Home > Journals > Minerva Obstetrics and Gynecology > Past Issues > Minerva Ginecologica 2015 April;67(2) > Minerva Ginecologica 2015 April;67(2):97-102

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLES   

Minerva Ginecologica 2015 April;67(2):97-102

Copyright © 2015 EDIZIONI MINERVA MEDICA

language: English

Short-term effect of vaginal erbium laser on the genitourinary syndrome of menopause

Gambacciani M. 1, Levancini M. 1, 2

1 Department of Obstetrics and Gynecology, Pisa University Hospital, Pisa, Italy; 2 Department of Obstetrics and Gynecology, Clinica Alemana, Universidad Del Desarrollo Santiago, Chile


PDF


AIM: In this study we evaluated the short term effects of vaginal erbium laser (VEL) in the treatment of postmenopausal women (PMW) suffering from genitourinary syndrome of menopause (GSM).
METHODS: Sixty-five PMW were evaluated before and after VEL treatment (1 treatment every 30 days, for 3 months). GSM symptoms were evaluated either with subjective (Visual Analog Scale, VAS) and objective (Vaginal Health Index Score, VHIS) measures. In addition, in 21 of these PMW suffering from mild-moderate stress urinary incontinence (SUI), the degree of incontinence was evaluated with the International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form (ICIQ-UI SF) before and after VEL treatments.
RESULTS: VEL treatment induced a significant decrease of VAS of both vaginal dryness, dyspareunia (P<0.01) and a significant (P<0.01) increase of VHIS). In addition, VEL treatment induced a significant (P<0.01) improvement of ICIQ-SF scores in PMW suffering from SUI. VEL was well tolerated with less than 2 % of patients discontinuing treatment due to adverse events.
CONCLUSION: VEL treatment significantly improves vaginal dryness, dyspareunia and mild-moderate SUI. Larger and long-term studies are needed to investigate the role of laser treatments in the management of GSM.

top of page